Anas Younes, M.D., director of Clinical and Translational Investigation in the Department of Lymphoma/Myeloma at M. D. Anderson, takes us into his lab where he's researching new targeted therapies for people with Hodgkin and non-Hodgkin lymphoma. His focus is on identifying opportunities to cause cell death or slow the growth of cells for certain tumor types.
He identifies the process involved in getting these targeted therapy drug combinations from the lab into Phase I clinical trials and eventually into standard treatment. 
Anas Younes,
M.D.,
is a professor in the Department of Lymphoma/Myeloma in
the Division of Cancer Medicine. For more information about targeted therapies for lymphoma, you can contact Younes via e-mail, Facebook or Twitter.
Follow DrAnasYounes on Twitter
Become
a fan of Dr. Younes on Facebook
Advances in Lymphoma Treatment Through Targeted Therapy
- Global Navigation
- About Us
- Locations
- Calendar
- Careers
- How You Can Help
- Children's Art Project
- Directory
- Contact Us
- Sitemap
- Patient and Cancer Information
- myMDAnderson
- Cancer Information
- Patient Information
- Care Centers & Clinics
- Children’s Cancer Hospital
- Services & Amenities
- Clinical Trials
- News and Publications
- Newsroom
- Publications
- Education and Research
- Departments, Programs & Labs
- Research at MD Anderson
- Education & Training
- Resources for Professionals
- For Employees
- Employee Resources
- Doing Business
- Vendors & Suppliers
- Partners & Affiliates
- State of Texas
- State of Texas Home Page
- Statewide Search (TRAIL)
- State Comptroller - Where the Money Goes
- Texas Homeland Security
- The University of Texas System
- Institution Resume
- Legal and Policy
- Legal Statements & Site Policies
- Stay Connected
- Emergency Alerts
- Emergency Alert Information
© 2013 The University of Texas MD Anderson Cancer Center
Leave a comment